Dizal Announces Successful Completion of IND Filing with US FDA for DZD9008

April 5, 2019 (GMT+8) - US FDA completed the review of DZD9008 IND (Investigational New Drug) application and concluded that Dizal may proceed with their proposed clinical investigation.

The release as fetched from its publisher. dizalpharma.com ↗